Effect of Container Shape,Age,and Visual Acuity on the Readability of Prescription Label Information in Persons With Visual Impairments

Abstract

Introduction: The readability of prescription drug labels has been found to be faster with labels attached to flat surfaces compared to round surfaces, in persons with visual impairment. This study extends this finding by examining the readability of drug labels, as measured by speed and accuracy, as they interact with factors of age and vision acuity across different container shapes. Methods: A repeated-measure, three-factor design (container shape, age, and vision acuity) with within-subject control was used with 54 adults with vision loss. Participants read 3 unique prescription drug labels across four container shapes, for a total of 12 trials. The amount of time needed to locate and read aloud 6 pieces of label information and the number of errors made in reading were outcome measures. Results: A two-way interaction was found between container shape and acuity for the time it takes to read the label information (Wald χ² = 22.836, df = 3, p < .001). The legally blind group required more time to read the label and had more variation in mean times across container type, compared to the low vision group. Both age and acuity showed statistically significant (p < 0.001) main effects on reading accuracy. Discussion: Within the legally blind acuity group, cylinder-shaped containers took statistically significantly longer to read compared to the flat label by 18 seconds. Increased age and lower visual acuity negatively affected reading accuracy, across all container shapes. Implications for Practitioners: Individuals with legal blindness may need more time to read prescription drug labels and may benefit from labels adhered to flat surfaces over traditional cylindrical containers. As medication safety is a critical skill for independent living, practitioners should assess their clients’ ability to access prescription drug label information, keeping in mind that these abilities may differ across different container shapes.

Keywords

medication management adverse drug events low vision aging

Get full access to this article

View all access options for this article.

References

American Foundation for the Blind. (2013). Special report on aging and vision loss. https://www.afb.org/research-and-initiatives/aging/special-report-aging-vision-loss

American Foundation for the Blind. (2015). AFBs Rx label enable campaign. https://www.afb.org/blindness-and-low-vision/your-rights/rx-label-enable-campaign

American Foundation for the Blind. (2019). Facts and figures on adults with vision loss. https://www.afb.org/research-and-initiatives/statistics/adults

American Society of Consultant Pharmacists Foundation and American Foundation for the Blind. (2008). Guidelines for prescription labeling and consumer medication information for people with vision loss. https://www.afb.org/blindness-and-low-vision/your-rights/rx-label-enable-campaign/guidelines-prescription-labeling

Bourgeois

F. T.

Shannon

M. W.

Valim

Mandi

K. D.

(2010). Adverse drug events in the outpatient setting: An 11-year national analysis. Pharmacoepidemiol Drug Safety, 19(9), 901–910. https://doi.org/10.1002/pds.1984

Centers for Disease Control and Prevention. (2015). Vision health initiative: Common eye disorders. https://www.cdc.gov/visionhealth/basics/ced/index.html

Connors

Lee

Curtis

A. B.

Kim

D. S.

Freeland

(2015). The effect of container shape on prescription drug label readability in adults with visual impairment. Journal of Visual Impairment & Blindness, 109(5), 371–382. https://doi.org/10.1177/0145482X1510900506

Dean

(2017). Prescription drug abuse among older adults. AARP Public Policy Institute. https://www.aarp.org/content/dam/aarp/ppi/2017/07/prescription-drug-abuse-among-older-adults.pdf

En-Vision America. (2009). AFB survey finds drug labeling puts people with vison loss at serious medical risk. https://www.envisionamerica.com/afb-survey-finds-drug-labeling-puts-people-with-vision-loss-at-serious-medical-risk/

10.

Faul

Erdfelder

Lang

A. G.

Buchner

(2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39(2), 175–191. https://doi.org/10.3758/bf03193146

11.

Dillon

C. F.

Burt

V. L.

(2010). Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS data brief (No. 42). Hyattsville, MD: National Center for Health Statistics. https://www.ncbi.nlm.nih.gov/pubmed/20854747

12.

IBM Corporation. (2012). IBM SPSS statistics for windows, version 21.0. Armonk, NY: IBM Corp.

13.

Institute of Medicine of the National Academies. (2000). To err is human: Building a safer health system. http://books.nap.edu/openbook.php?record_id=9728

14.

Institute of Medicine of the National Academies. (2006). Preventing medication errors: Quality chasm series consensus report. http://books.nap.edu/openbook.php?record_id=11623

15.

Interactive Visual Acuity Chart . (n.d.). University of buffalo interactive visual acuity chart. http://www.smbs.buffalo.edu/oph/ped/IVAC/IVAC.html

16.

Kantor

E. D.

Rehm

C. D.

Haas

J. S.

Chan

A. T.

Giovannucci

E. L.

(2015). Trends in prescription drug use among adults in the United States from 1999-2012. JAMA, 314(17), 1818–1831. https://doi.org/10.1001/jama.2015.13766

17.

Kaufman

D. W.

Kelly

J. P.

Rosenberg

Anderson

T. E.

Mitchell

A. A.

(2002). Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. Journal of the American Medical Association, 287(3), 337–344. https://doi.org/10.1001/jama.287.3.337

18.

Keppel

Zedeck

(1989). Data analysis for research designs: Analysis of variance and multiple regression/correlation approaches. New York, NY: Freeman.

19.

Lærd Statistics. (2018). Measures of central tendency. Lund Research Ltd. https://statistics.laerd.com/statistical-guides/measures-central-tendency-mean-mode-median.php

20.

Lee

(2012). Effect of container shape on label readability among persons with vision loss. Unpublished raw data.

21.

Martin

C. B.

Hales

C. M.

Ogden

C. L.

(2019). Prescription drug use in the United States, 2015–2016. NCHS Data Brief, no 334. Hyattsville, MD: National Center for Health Statistics. https://www.cdc.gov/nchs/data/databriefs/db334-h.pdf

22.

Mather

Jacobsen

L. A.

Pollard

K. M.

(2015). Population Bulletin: Aging in the United States. Population Reference Bureau, 70(2), 1–19. https://www.prb.org/wp-content/uploads/2016/01/aging-us-population-bulletin-1.pdf

23.

McMahon

J. M.

Curtis

(2009). Methods of reading information on labels of prescription medications by persons who are visually impaired. Journal of Visual Impairment & Blindness, 103(5), 303–308. https://journals.sagepub.com/doi/pdf/10.1177/0145482X0910300508

24.

Merck Institute of Aging & Health. (2004). The state of aging and health in America. https://www.cdc.gov/aging/pdf/State_of_Aging_and_Health_in_America_2004.pdf

25.

National Academies of Sciences, Engineering, and Medicine. (2015). Health literacy: Past, present, and future: Workshop summary. Washington, DC: The National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK310866/pdf/Bookshelf_NBK310866.pdf

26.

National Center for Health Statistics. (2013). Health, United States, 2013: With special feature on prescription drugs. Hyattsville, MD. https://www.ncbi.nlm.nih.gov/books/NBK209224/pdf/Bookshelf_NBK209224.pdf

27.

National Center for Health Statistics. (2017b). Summary health statistics: National health Interview survey: Table A-6a. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2017_SHS_Table_A-6.pdf

28.

National Center for Health Statistics. (2017). Therapeutic drug use. Table 79 https://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm

29.

National Eye Institute. (2019). Low vision defined. National Institutes of Health. https://www.nei.nih.gov/eyedata/lowvision.asp

30.

Patient Safety Network. (2019). Medication errors and adverse drug events. Agency for Healthcare Research and Quality. https://psnet.ahrq.gov/primers/primer/23/Medication-Errors-and-Adverse-Drug-Events

31.

Shrank

Avorn

Rolon

Shekelle

(2007). Effect of content and format of prescription drug labels on readability, understanding, and medication use: A systematic review. Annals of Pharmacotherapy, 41(5), 783–801. http://www.ncbi.nlm.nih.gov/pubmed/17426075

32.

Shrank

W. H.

Gleason

P. P.

Canning

Walters

Heaton

A. H.

Jan

Patrick

Brookhart

M. A.

Schneeweiss

Solomon

D. H.

Avorn

Choudhry

N. K.

(2009a). Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label. Journal of General Internal Medicine, 24(5), 570–578. https://doi.org/10.1007/s11606-009-0924-x

33.

Shrank

W. H.

Patrick

Gleason

P. P.

Canning

Walters

Heaton

A. H.

Jan

Brookhart

M. A.

Schneeweiss

Solomon

D. H.

Wolf

M. S.

Avorn

Choudhry

N. K.

(2009b). An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes. Medical Care, 47(9), 1031–1035. https://doi.org/10.1097/MLR.0b013e3181a81181

34.

United States Access Board Working Group on Accessible Prescription Drug Container Labels. (2013). Best practices for making prescription drug container label information accessible to person who are blind or visually-impaired or who are elderly. http://www.access-board.gov/guidelines-and-standards/health-care/about-prescription-drug-container-labels/working-group-recommendations

35.

United States Pharmacopeial Convention. (2012). First universal standards guiding content, appearance of prescription container labels to promote patient understanding of medication instructions. https://www.prnewswire.com/news-releases/first-universal-standards-guiding-content-appearance-of-prescription-container-labels-to-promote-patient-understanding-of-medication-instructions-173272741.html

36.

World Health Organization. (2002). Health statistics and information systems: Proposed working definition of an older person in Africa for the MDS project. http://www.who.int/healthinfo/survey/ageingdefnolder/en/

37.

World Health Organization. (2017). The third WHO global patient safety challenge: Medication without harm. https://www.who.int/patientsafety/medication-safety/en/